Paper Details

  1. Home
  2. Paper Details

Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.

Author: AparasuRajender, EstesEmily, ReddyDoodipala Samba, TalwarAshna

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Cannabidiol (CBD) has been approved for refractory epilepsy syndromes. This systematic review and meta-analysis of randomized controlled trials found that CBD treatment was associated with a significant reduction in seizure frequency in patients with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, compared to placebo.
Paper Details　
Original Abstract of the Article :
Antiseizure medications (ASMs) are the mainstay for the treatment of seizure disorders. However, about one-third of people with epilepsy remain refractory to current ASMs. Cannabidiol (CBD) has recently been approved as ASM for three refractory epilepsy syndrome indications in children and adults. I...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.expneurol.2022.114238

データ提供：米国国立医学図書館（NLM）

Clinical Efficacy and Safety of Cannabidiol for Pediatric Refractory Epilepsy Indications: A Systematic Review and Meta-Analysis

The search for effective treatments for epilepsy, like a journey through a vast and unforgiving desert, continues. This study, like a seasoned explorer, delves into the potential of cannabidiol (CBD) for treating pediatric refractory epilepsy. The researchers conducted a systematic review and meta-analysis of existing studies, hoping to gain a comprehensive understanding of CBD's efficacy and safety in this challenging condition.

The researchers found that CBD, when administered orally, was significantly more effective than placebo in reducing seizure frequency in children with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. While CBD was associated with increased side effects, such as diarrhea, somnolence, and sedation, these were generally manageable. The study suggests that CBD could be a valuable treatment option for children with refractory epilepsy.

Exploring the Therapeutic Potential of Cannabidiol

This study highlights the potential of CBD as a promising treatment option for children with refractory epilepsy. The research findings encourage further investigation into CBD's efficacy and safety in various epilepsy syndromes.

Improving Treatment Options for Epilepsy

This study underscores the need for more effective treatment options for children with refractory epilepsy. The research findings suggest that CBD could be a valuable addition to the existing armamentarium of therapies, potentially improving outcomes and quality of life for patients.

Dr. Camel's Conclusion

Epilepsy, like a desert storm, can be a relentless and unpredictable force. This study provides valuable insights into the therapeutic potential of CBD for pediatric refractory epilepsy. The findings encourage further exploration of CBD's efficacy and safety, offering hope for new and effective treatment options for children battling this challenging condition.

Date :
  1. Date Completed 2023-04-03
  2. Date Revised 2023-04-03
Further Info :

Pubmed ID

36206805

DOI: Digital Object Identifier

10.1016/j.expneurol.2022.114238

Related Literature

Article Analysis
・Side Effects of clobazam
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.